ISCO · International Stem Cell CORP
Market Cap
$2.80M
Shares
8.00M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.38
Open$0.36
Day$0.30–0.38
52W close$0.12–0.51
Avg vol 30d32K
Short int8K · 0.1% float · 1.1d
Short vol10%
DataJan 2020–Aug 2026
Filing10-Q · Aug 13
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 13, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.70
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+111%
above
Price vs 50-day avg
+38%
above
RSI (14)
51
neutral
MACD trend
Negative
52-week position
67%
mid-range
Momentum
relative strength
1-month return
+42%
trailing
6-month return
+155%
trailing
YTD return
+173%
this year
Relative strength
+141%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 50d above 200d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.10% of float · ▲ +345.3% MoM · 1.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Squeeze score
44
elevated · 0–100
Fundamentals
Revenue growth
+4%
Y/Y
EPS growth
−67%
Y/Y
Free cash flow
$-35.0K
Quant / Vol
risk profile
Volatility
216%
annualized · 1-yr
Max drawdown
−40%
past year
ATR
20.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+111%
Bullish
Price vs 50-day avg
+38%
Bullish
RSI (14)
51
Neutral
MACD trend
Negative
Bearish
52-week position
67%
Neutral
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50d $0 › 200d $0 — 50d above 200d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.10% of float · ▲ +345.3% MoM · 1.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Price context
position in its 52-week range
Range low $0
Now $0 · 67%
Range high $1
vs 200-day avg +111%
vs 50-day avg +38%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ISCO
this stock
International Stem Cell CORP
|
$2.80M | +172.9% | +4.1% | — | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +20.1% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.77B | +3.5% | +20.8% | 19.7 | 2.3% |
|
ARGX
Argenx SE
|
$64.16B | +22.7% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.51B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionShort & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ISCO | -23.3% | +41.5% | +154.7% | +41.5% | +172.9% |
| SPY | +0.5% | +1.2% | +13.3% | +2.7% | +12.5% |
| vs SPY | -23.7% | +40.3% | +141.5% | +38.8% | +160.5% |